Mental Health

Pharmacy professionals deserve the right to pursue mental health care without fear of losing their jobs. The Wellbeing First Champion Challenge is helping change this.

In hospital and critical care settings, pharmacists can play a significant role in educating other health care providers about treatment options, proper dosing, and more.

The addition of samidorphan can support the antipsychotic efficacy of olanzapine while mitigating associated weight gain.

The authors recommend that longer assessments with lengthier interventions should be performed to assess potential benefits.

Postpartum depression (PPD) rates also had notable increases in those with class I and class II/III obesity.

Lenora Newsome, PD, president of the National Association of Boards of Pharmacy, explores how pharmacists can support mental health.

The strongest association is found between asthma and the risk of attention deficit/hyperactivity disorder, though these links do not equate to causality.

The data also shows similar results for children with mothers who have pre-pregnancy body mass index outside of normal range.

Eladocagene exuparvovec-tneq is the first FDA-approved gene therapy for individuals with aromatic L-amino acid decarboxylase deficiency.

In the trial, lumateperone had a significantly longer time to relapse in patients treated compared to placebo.

The demanding nature of pharmacy programs often leaves little time for self-care, social activities, or hobbies, leading to an imbalance that can foster burnout.

The study found that this patient population was about 25% more likely to have serious mental health issues after childbirth.

The results found that women, non-binary, and sexual minority students are at the highest risk.

The FDA announces a Class II recall for the lot #220128, which were reported to contain the presence of nitrosamine.

Women are more likely to face burnout because they are often balancing both workload and family or home life responsibilities.

Pharmacogenomic testing can help identify patients' genetic profiles, revealing why certain drugs may be less effective or cause adverse effects.

Offering pharmacy professionals insights into the benefits, importance and challenges associated with switching patients to long-acting injectables to treat schizophrenia.

Video chatting, texting, watching videos, and playing video games were activities most commonly associated with depressive symptoms in adolescents.

However, the results also showed that vaccination rates were lower in those who are unmedicated for their mental illness and those with substance use disorders.

According to the authors, being able to identify mood disturbances through passive digital biomarker data can be promising in next-generation predictive, personalized mental health diagnostics.

When considering the 3-stage framework, perhaps a greater emphasis on pre-treatment phase research could help identify some of the more individual traits used to better predict patient outcomes.

Xanomeline and trospium chloride is the first in a new class, offering a new approach with selectively targeting M1 and M4 receptors.

In adolescents, a comprehensive model using behavioral and MRI data had a prediction accuracy of 0.83, which was higher than single data type models.

Using the term "pseudodementia" contributes to the mismanagement and mistreatment of the disease.

Additionally, the authors are concerned by the lack of increase in depressive or anxiety diagnoses, indicating potential barriers to care.

The authors urge that screening, prevention, and treatment of anxiety and depression should be important health care priorities for youth who have chronic pain.

The findings demonstrate a need for additional health care provider training and resources for birthing people with intellectual and developmental disabilities.

Those with an aneurysm diagnosis who were younger than 40 years of age were observed to have an even higher risk.

Risk of developing anxiety or depression is highest within the first year after cardiovascular hospitalization.

Previously, an independent advisory panel for the FDA rejected the use of MDMA-assisted therapy for posttraumatic stress disorder (PTSD), citing concerns of the reliability of the clinical trial data.